Immunogenicity and reactogenicity of a combined hepatitis A/B candidate vaccine: First results

Liver

Volumn 16, Issue 4, 1996, Pages 271-273

  Kallinowski, B ^a,c   Bock, H L ^b   Clemens, R ^b   Theilmann, L ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b SmithKline Beecham   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Hepatitis A vaccination; Hepatitis B vaccination; Immunogenicity

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE;

ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MIXTURE; FEMALE; HEADACHE; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NAUSEA; SEROCONVERSION; SKIN MANIFESTATION; VACCINATION; VOMITING;

EID: 0029775853     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0676.1996.tb00742.x     Document Type: Article

References (24)

1. GUPTA S, SHAFRITZ D A. Viral hepatitis B and D. In: Prieto J, Rodes J, Shafritz D A, eds. Hepatobiliary disease. Berlin: Springer, 1992: 526-542.
2. ANDRÉ F. Overview of a 5-year clinical experience with the yeast derived hepatitis B vaccines. Vaccine (suppl.) 1990: 8: 74-78.
3. FRÖSNER G G, PAPAEVANGELOU G, BÜTLER R, et al. Antibody against hepatitis A in seven European countries. Am J Epidemiol 1979: 110: 63-68.
4. FRÖSNER G G. Epidemiology of hepatitis A. In: Deinhardt F, ed. Viral hepatitis: laboratory and clinical science. New York: Marced Dekkes, 1983: 201-212.
5. STEFFEN R. Reisemedizin. Heidelberg: Springer, 1984: 90-96.
6. LEDNAR W M, LEMON S M, KIRKPATRICK J W, REDFIELD R R, FIELDS M L, KELLEY P W. Frequency of illness associated symptoms with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985: 122: 226-233.
7. HADLER S C, WEBSTER H M, ERBEN J J, SWANSON J E, MAYNARD J E. Hepatitis A in day-care centers: a community-wide assessment. N Engl J Med 1980: 302: 1222-1227.
8. ANDRÉ F, HEPBURN A, HONDT E. Inactivated candidate vaccines for hepatitis A. In: Melnick JI, ed. Progress in medical virology. Basel: Karger, 1990: 37: 72-95.
9. KALLINOWSKI B, GMELIN K, KOMMERELL B, et al. Immunogenicity, reactogenicity and consistency of a new, inactivated hepatitis A vaccine - a randomized multicentre study with three consecutive vaccine lots. Vaccine 1992: 10: 500-502.
10. KOLLARITSCH H, HOFMANN H, KUNZ CH, et al. Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine 1990: 8: 581-584.
11. TILZEY A J, PALMERS J, BARROW S, et al. Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. Br Med J 1992: 304: 1272-1276.
12. WIEDERMANN G, AMBROSCH F, KOLLARITSCH H, et al. Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy volunteers. Vaccine 1990: 8: 581-584.
13. AMBROSCH F, WIEDERMANN G, ANDRÉ F E, D'HONDT E, DELEM A, SAFARY A. Comparison of HAV antibodies induced by vaccination, passive immunization and natural infection. In: Hollinger F, Lemon S M, Margolis H S, eds. Viral hepatitis and liver disease. Baltimore: Williams and Wilkins, 1991: 732-739.
14. BERGER J, JUST M. Vaccination against hepatitis A: control 3 years after the first vaccination. Vaccine 1992: 10: 295-298.
15. SCHMID K, STREBL K, HECK K J, WELTLE D, RAITHEL H J. Wirksamkeit und verträglichkeit gentechnologisch hergestellter impfstoffe gegen hepatitis B - eine vergleichende gegenüberstellung. Gesundh Wes 1992: 54: 219-223.
16. WIEDERMANN G, AMBROSCH F, KREMSNER P, et al. Reactogenicity and immunogenicity of different lots of a yeast derived hepatitis B vaccine. Postgrad Med J 1987: 63: 109-112.
17. FRISCH-NIGGEMEYER W, AMBROSCH F, HOFMANN H. The assessment of immunity against hepatitis B after vaccination. J Biol Stand 1986: 14: 255-258.
18. WINTER A P, FOLLETT E, MCINTYRE J, STEWART J, SYMINGTON I. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 1994: 12: 771-772.
19. CARRAO G, CALLERI M, ZOTTI M. Immune response to anti-HBV vaccination: study of conditioning factors. Eur J Epidemiol 1988: 4: 492-496.
20. HESS G, HINGST V, CSEKE J, BOCK H, CLEMENS R. Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination. Eur J Clin Microbiol Infect Dis 1992: 11: 334-340.
21. SHERMAN K, DODD R. Alanine aminotransferase levels among volunteer blood donors: geographic variation and risk factors. J Infect Dis 1982: 3: 383-386.
22. AMBROSCH F, FRISCH-NIGGEMEYER W, KREMSNER P, et al. Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. Postgrad Med J 1987: 63: 129-135.
23. VAN DAMME P, THOELEN S, CRAMM M, SAFARY A, MEHEUS A. Reactogenicity and immunogenicity of a combined hepatitis A and B vaccine in healthy adults. In: Nishioka K, Suziki H, Mishiro L, Oda T, eds. Viral hepatitis and liver diseases. Tokyo, Berlin: Springer, 1994: 514-516.
24. AMBROSCH F, ANDRÉ F E, DELEM A, et al. Simultaneous vaccination against hepatitis A and B: results of a controlled study. Vaccine 1992: 10: 142-145.